Your Health, We Care
In multiple clinical trials, Ceritinib has shown significant efficacy. In the ASCEND-4 trial, the median progression free survival (PFS) of patients treated with Ceritinib was 16.6 months, while the PFS of patients receiving chemotherapy was only 8.1 months, indicating that Ceritinib has a significant advantage in delaying disease progression.
In addition, Ceritinib has been shown to be effective in treating ALK positive NSCLC patients who develop resistance or intolerance to crizotinib, providing a new treatment option for these patients.
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
